KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Other financing activities (2020 - 2025)

Historic Other financing activities for Esperion Therapeutics (ESPR) over the last 6 years, with Q1 2025 value amounting to $7.5 million.

  • Esperion Therapeutics' Other financing activities changed N/A to $7.5 million in Q1 2025 from the same period last year, while for Sep 2025 it was -$2.1 million, marking a year-over-year decrease of 12173.73%. This contributed to the annual value of $29000.0 for FY2024, which is 3809.52% up from last year.
  • Per Esperion Therapeutics' latest filing, its Other financing activities stood at $7.5 million for Q1 2025.
  • Esperion Therapeutics' 5-year Other financing activities high stood at $9.6 million for Q3 2024, and its period low was -$9.6 million during Q4 2024.
  • Moreover, its 5-year median value for Other financing activities was $134500.0 (2021), whereas its average is $971375.0.
  • In the last 5 years, Esperion Therapeutics' Other financing activities surged by 33800.0% in 2022 and then crashed by 4580000.0% in 2024.
  • Quarter analysis of 5 years shows Esperion Therapeutics' Other financing activities stood at $390000.0 in 2021, then plummeted by 212.31% to -$438000.0 in 2022, then soared by 104.79% to $21000.0 in 2023, then crashed by 45800.0% to -$9.6 million in 2024, then surged by 178.15% to $7.5 million in 2025.
  • Its last three reported values are $7.5 million in Q1 2025, -$9.6 million for Q4 2024, and $9.6 million during Q3 2024.